Multimodal Morpho-functional Study in Glaucoma Patients-Citicoline Oral Solution

NAActive, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 25, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

July 31, 2025

Conditions
Primary Open Angle Glaucoma
Interventions
DIETARY_SUPPLEMENT

Citicoline

"The patient will be given 10 ml of Citicoline oral solution (Neurotidine ®) once a day in the morning for 1 year. To patients will be given 4 bottles containing 500 ml of Citicoline and the relative instructions for administration. After 6 months, the patient will bring back the used bottles and will be given additional 4 bottles containing Citicoline (Neurotidine ®). Again at the end of this 6 month period the patient will bring back the used bottles.~Each bottle of Neurotidine will contain: water; fructose; Citicoline (500 mg per 10 ml); acidity regulators: sodium citrate, sodium hydroxide; preservative: potassium sorbate; dye: riboflavine."

DIETARY_SUPPLEMENT

Placebo

The patient will be given 10 ml of an oral solution of Placebo. Each bottle of Placebo, the solution of which will be indistinguishable from the active product in terms of appearance and flavor, will contain: water; fructose; acidity regulators: sodium citrate, sodium hydroxide; preservative: potassium sorbate; dye: riboflavin

Trial Locations (2)

00184

Fondazione BIetti, Britannico Hospital, Roma

00199

Fondazione G.B. Bietti-IRCCS, Rome

All Listed Sponsors
lead

Fondazione G.B. Bietti, IRCCS

OTHER